Meta-analysis of prostate-specific antigen and digital rectal examination as screening tests for prostate carcinoma

Journal of the American Board of Family Practice

Volumn 16, Issue 2, 2003, Pages 95-101

  Mistry, Kishor ^a,c   Cable, Greg ^b  

^a OVERLOOK HOSPITAL   (United States)

^b Atlantic Health   (United States)

^c NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ARTICLE; CALCULATION; CANCER DIAGNOSIS; CANCER LOCALIZATION; CANCER PATIENT; CANCER SCREENING; CANCER STAGING; CLINICAL TRIAL; DATA BASE; DEVELOPED COUNTRY; DIAGNOSTIC ACCURACY; DIGITAL RECTAL EXAMINATION; HUMAN; META ANALYSIS; PREDICTOR VARIABLE; PROSTATE CARCINOMA; SENSITIVITY AND SPECIFICITY; STATISTICAL ANALYSIS; SYMPTOM; SYSTEMATIC REVIEW; ADULT; AGED; BLOOD; CARCINOMA; MALE; MASS SCREENING; METHODOLOGY; MIDDLE AGED; OUTCOME ASSESSMENT; PHYSICAL EXAMINATION; PREDICTION AND FORECASTING; PROSTATE TUMOR; RECTUM;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA; HUMANS; MALE; MASS SCREENING; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); PHYSICAL EXAMINATION; PREDICTIVE VALUE OF TESTS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RECTUM; SENSITIVITY AND SPECIFICITY;

EID: 0041746616     PISSN: 08938652     EISSN: 15448770     Source Type: Journal    
DOI: 10.3122/jabfm.16.2.95     Document Type: Article

References (35)

1. Greenelee RT, Hill-Harmon MB, Murry T, Thun M. Cancer statistics, 2001. CA Cancer J Clin 2001;51:15-36.
2. Godley PA. Prostate cancer screening: promise and peril - a review. Cancer Detect Prev 1999;23:316-24.
3. Jubelirer SJ, Tierney JP, Oliver S, et al. The value of prostatic specific antigen in prostate cancer screening in the community. W Va Med J 1994;90:140-2.
4. Marwick C. Global review of diet and cancer links available. JAMA 1997;278:1650-1.
5. Maattanen L, Auvinen A, Stenman UH, et al. European randomized study of prostate cancer screening: first-year results of the Finnish trial. Br J Cancer 1999;79:1210-4.
6. Kuriyama M, Wang MC, Papsidero LD, et al. Quantitation of prostate-specific antigen in serum by a sensitive enzyme immunoassay. Cancer Res 1980;40:4658-62.
7. Higashihara E, Nutahara K, Kojima M, et al. Significance of free prostate-specific antigen and gamma-seminoprotein in the screening of prostate cancer. Prostate Suppl 1996;7:40-7.
8. Jewett HJ, Bridge RW, Gray GF Jr, Shelley WM. The palpable nodule of prostatic cancer. Results of 15 years after radical excision. JAMA 1968;203:403-6.
9. Osterling JE. Early detection of prostate cancer. Decreasing the mortality rate. Minn Med 1996;79:46-9.
10. Guide to clinical preventive services. 2nd ed. Report of the US Preventive Services Task Force. Baltimore, Md: Williams & Wilkins 1996:119-34.
11. Kramer BS, Brown ML, Prorok PC, Potosky AL, Gohagan JK. Prostate cancer screening: what we know and what we need to know. Ann Intern Med 1993;119:914-23.
12. Woolf HS. Screening for prostate cancer with prostate-specific antigen: an examination of evidence. N Engl J Med 1995;333:1401-5.
13. Zoorob R, Anderson R, Cefalu C, Sidani M. Cancer screening guidelines. Am J Fam Physician 2001;63:1101-12.
14. Bangma CH, Kranse R, Blijenberg BG, Schroder F. The value of screening tests in the detection of prostate cancer. Part II: retrospective analysis of free/total prostate-specific analysis ratio, age-specific reference ranges, and PSA density. Urology 1995;46:779-84.
15. Brett TD. An analysis of digital rectal examination and serum-prostate-specific antigen in the early detection of prostate cancer in general practice. Fam Pract 1998;15:529-33.
16. Bretton PR. Prostate-specific antigen and digital rectal examination in screening for prostate cancer: a community-based study. South Med J 1994;87:720-3.
17. Gustafsson O, Mansour E, Norming U, Carlsson A, Tomblom M, Nyman CR. Prostate-specific antigen (PSA), PSA density and age-adjusted PSA reference values in screening for prostate cancer - a study of a randomly selected population of 2,400 men. Scand J Urol Nephrol 1998;32:373-7.
18. Horninger W, Reissigl A, Rogatsch H, et al. Prostate cancer screening in Tyrol, Australia: experience and results. Eur Urol 1999;35:523-38.
19. Imai K, Ichinose Y, Kubota Y, et al. Clinical significance of prostate specific antigen for early stage prostate cancer detection. Jpn J Clin Oncol 1994;24:160-5.
20. Imai K, Ichinose Y, Kubota Y, Yamanaka H, Sato J. Diagnostic significance of prostate specific antigen and the development of a mass screening system for prostate cancer. J Urol 1995;154:1085-9.
21. Reissigl A, Pointner J, Horninger W, et al. PSA-based screening for prostate cancer in asymptomatic younger males: pilot study in blood donors. Prostate 1997;30:20-5.
22. Stenman UH, Hakama M, Knekt P, Aromaa A, Teppo L, Leinonen J. Serum concentrations of prostatic specific antigen and its complex with alpha1-antichymotrypsin before diagnosis of prostate cancer. Lancet 1994;344:1594-8.
23. Tsukamoto T, Kumamoto Y, Masumori N, et al. Mass screening for prostate carcinoma: a study in Hokkaido, Japan. Eur Urol 1995;27:177-81.
24. Cochran WG. Sampling techniques. 3rd ed. New York: John Wiley & Sons, 1977:89-96.
25. Woolf HS. Prostate cancer: to screen or not to screen? Commentary. Oncology 1997; 11:451-2.
26. Tornblom M, Norming U, Adolfsson J, et al. Diagnostic value of percent free prostate-specific antigen: retrospective analysis of a population-based screening study with emphasis on men with PSA levels less than 3 ng/mL. Urology 1999;53:945-50.
27. Lodding P, Aus G, Bergdahl S, et al. Characteristics of screening detected prostate cancer in men 50 to 66 years old with 3 to 4 ng/mL prostate-specific antigen. J Urol 1998;159:899-903.
28. Svetec D, Thompson IM. PSA screening - current controversy. Ann Oncol 1998;9:1283-8.
29. Scardino PT. Early detection of prostate cancer. Urol Clin North Am 1989;16:635-55.
30. Rationale for randomised trials of prostate cancer screening. The International Prostate Screening Trial Evaluation Group. Eur J Cancer 1999;35: 262-71.
31. Zappa M, Ciatto S, Bonardi R, Mazzotta A. Overdiagnosis of prostate carcinoma by screening: An estimate based on the results of the Florence screening pilot study. Ann Oncol 1998;9:1297-1300.
32. Brawer MK. prostate-specific antigen. Diagn Clin Testing 1990;28:16-21.
33. Oesterling JE. Prostate-specific antigen. Cancer 1995;75:1795-1804.
34. Statistical abstract of the United States. 17th ed. US Department of Commerce, Economics and Statistics Administration, Bureau of the Census. Lantham, Md: Bernan Press, 1997:15.
35. de Koning HJ, Auvinen A, Berenguer Sanchez AB, et al. Large-scale randomized prostate cancer screening trials: program performances in the European Randomized Screening for Prostate Cancer trial and the Prostate, Lung, Colorectal and Ovary cancer trial. Int J Cancer 2002;97:237-44.